Chemotherapy-induced oral mucositis: New approaches to prevention and management

Expert Opinion on Drug Safety

Volumn 4, Issue 2, 2005, Pages 193-200

  Wright, Janice ^a   Feld, Ronald ^a   Knox, Jennifer ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical practice guideliness; Mucositis pathophysiology; Oral assessment; Oral care; Oral mucositis; Stomatitis

Indexed keywords

ACICLOVIR; AMIFOSTINE; ANTHRACYCLINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BENZYDAMINE; CAPECITABINE; CHLORHEXIDINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GELCLAIR; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; METHOTREXATE; PALIFERMIN; PLACEBO; PURINE ANTAGONIST; REACTIVE OXYGEN METABOLITE; REPIFERMIN; SUCRALFATE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MOUTH HYGIENE; MOUTH MUCOSA; MULTIMODALITY CANCER THERAPY; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; RADIATION INJURY; REVIEW; RIGOR; RISK ASSESSMENT; RISK FACTOR; STOMATITIS; TASTE DISORDER; URTICARIA; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BENZYDAMINE; CRYOTHERAPY; FIBROBLAST GROWTH FACTOR 7; GLUTAMINE; HUMANS; QUALITY OF LIFE; RISK FACTORS; STOMATITIS;

EID: 20944450198     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.2.193     Document Type: Review

References (56)

1. SCHUBERT MM: Oral Mucositis in Cancer Care. Oncology Special Edition (2004) 7:51-55.
2. SONIS S, ELTING L, KEEFE, D et al.: Perspectives on cancer therapy-induced mucosal injury. Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 100(Suppl.):1995-2012.
3. RUBENSTEIN E, PETERSON D, SCHUBERT M et al.: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 100(Suppl.9):2026-2046.
4. KNOX J, PUODZIUNAS ALV, FELD R: Chemotherapy-induced oral mucositis prevention and management. Drugs Aging (2000) 17(4):257-267.
5. ELTING L, COOKSLEY C, CHAMBERS M et al.: The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucostitis. Cancer (2003) 98:1531-1539.
6. AVRITSCHER E, COOKSLEY C, ELTING L: Scope and epidemiology of cancer-therapy induced oral and gastrointestinal mucositis. Semin. Oncol. Nursing (2004) 20(1):3-8.
7. LOCKHART PB, SONIS ST: Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J. Dermatol. Surg. Oncol. (1981) 7:1019-1025.
8. SONIS ST: Mucositis as a biologic process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. (1998) 34(1):39-43.
9. BROWN C, WINGARD J: Clinical consequences of Oral mucositis. Semin. Oncol. Nurs. (2004) 20(1):16-21.
10. BIRON P, SEBBAN C, GOURMET R et al.: Research controversies in management of oral mucositis. Support. Care Cancer (2000) 8:68-71.
11. DODD MJ, DIBBLE S, MIASKOWSKI C et al.: A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis. J. Pain Symptom Manage. (2001) 21:498-505.
12. BELLM LA, EPSTEIN JB, ROSE-PED A, MARTIN P, FUCHS HJ: Patient reports of complications of bone marrow transplantation. Support. Care Cancer (2000) 8:33-39.
13. SONIS ST, OSLER G, FUCHS H et al.: Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J. Clin. Oncol. (2001) 19:2201-2205.
14. ELTING L, PETERSON D, SONIS ST: Late-breaking information from the 2004 ASCO Annual Meeting. Oral Mucositis Newsletter (2004) 1(1):1-12.
15. BALADUCCI L, EXTERRMAN M: Management of cancer in the older person: a practical approach. Oncologist (2000) 20:224-237.
16. SONIS ST, PETERSON DE, MCGUIRE DB, WILLIAMS DA: Prevention of mucositis in cancer patients. J. Natl. Cancer Inst. Monogr. (2001) 29:1-2.
17. MILLER AB et al.: Cancer (1981) 4:7207-7219.
18. FAHLKE J: High-dose therapy with combined 5-flourouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. Int. J. Colorectal Dis. (1999) 14:128-130.
19. PETERSON D, BECK S, KEEFE D: Novel therapies. Semin. Oncol. Nursing (2004) 20(1):53-58.
20. EPSTEIN JB, SILVERMAN S, PAGGIARINO DA et al.: Benzydmine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter,randomized,double blind,placebo controlled clinical trial. Cancer (2001) 15:875-885.
21. PRADA A, CHIESA F: Effects of benzydamine on oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int. J. Tissue React. (1987) 9:115-119.
22. BRIZEL D, WASSERMAN T, HENKE M et al.: Phase III randomized trial of amifostine as radioprotector in head and neck cancer. J. Clin. Oncol. (2000) 18:3339-3345.
23. KOMAKI R, LEE JS, KAPLAN B et al.: Randomized Phase III study of chemoradiation with or without amifostine for patients with favourable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin. Radiat. Oncol. (2002) 12(Suppl. 1):46-49.
24. RADES D, FEHLAUER F, BAJROVIC A et al.: Serious adverse effects of amifostine during radiotherapy of in head and neck cancer patients. Radiother. Onc. (2004) 70:261-264.
25. TROTTI A, BELLM L, EPSTEIN J et al.: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literarure review. Radiother. Oncol. (2003) 66:253-262.
26. MAHOOD DJ, DOSE AM, LOPRINZI CL et al.: Inhibition of flourouracil-induced stomatitis by oral cryotherapy. J. Clin. Oncol. (1991) 9:449-52.
27. CASINU S, FEDELLI A, FEDELLI SL et al.: Oral cooling (Cryotherapy), an effective treatment for the prevention of 5-fluorouracil-related stomatitis. Eur. J. Cancer B Oral Oncol. (1994) 30B:234-236.
28. ROCKE LK, LOPRINZI CL, LEE JK et al.: A randomised trail of two different durations of oral cryotherapy for prevention of 5-fluorouracil-induced stomatitis. Cancer (1993) 72:2234-2238.
29. PETERSON DE, PETIT RG: Phase III study: AES-14 in chemotherapy patients at risk for mucositis. Proceedings of American Society of Clin. Oncol. Chicago, USA (2003) (Abstract 2917) 22:275.
30. SPIELBERGER R, EMMANOUILISE SC, STIFF P et al.: Use of recombinant human karatinocyte growth factor (rHUKGF) can reduce severe oral mucositis in patients with hematological malignancies undergoing autologous, peripheral blood progenitor cell transplantation. Proceedings of the American Society of Clin. Oncol. Chigago, USA (2003).
31. NEAL J, MEROPOL RA, SOMER JG: Randomized Phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J. Clin. Oncol. (2003) 21(8):1452-1458.
32. STIFF P: Oral mucositis in the cancer treatment setting: prospects for improved management. Proceedings of the Multinational Association of Support. Care Cancer. Miami, USA (2004).
33. HUMAN GENOME SCIENCES: Results of Phase II repifermin clinical trial demonstrate safety and efficacy in patients with cancer-therapy-induced mucositis. Press Release Rockville, USA (2003).
34. ROSSI A, ROSATI G, COLARUSSO D, MANZIONE L: Subcutaneous granulocyte-macrophage colony stimulating factor in mucositis induced by an adjuvant 5-flourouracil plus leucovorin regimen. A Phase II study and review of the literature. Oncology (2003) 64(4):352-360.
35. DAZZI C, CARIELLO A, GIOVANIS P et al.: Prophylaxis with GM-CSF mouthwashes does not reduce the frequency and duration of severe oral mucositis in patients with solid tumours undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann. Oncol. (2003) 14(4):559-563.
36. PENTENGELL R, GURNEY H, RADFORD JA et al.: Granulocyte colony-hstimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 80:1430-1436.
37. FOOTE RL, LOPRINZI CL, FRANK AR et al.: Randomized trial of Chlorhexidine mouthwash for alleviation of radiation induced-mucositis. J. Clin. Oncol. (1994) 12:2630-2633.
38. PITTEN FA, KIEFER T, BUTH C et al.: Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine based oral rinse? A double blind, block-randomized, controlled study. J. Hosp. Infect. (2003) 53:283-291.
39. BUSCHEL PC: Gelcair® oral gel. Clin. J. Oncol. Nurs. (2003) 7(1):109-110.
40. INNOCENTI M, MOSCATELLI G, LOPEZ S: Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J. Pain Symptom Manage. (2002) 24(5):456-457.
41. SMITH T: Gelclair:managing the symptoms of oral mucositis. Hosp. Med. (2001) 62(10):623-626.
42. D'ANDREA N, GIORGIUTTI E, DECORTI D et al.: Oral pharyngeal mucositis: nursing assessment on the efficacy of a new treatment. Ann. Oncol. (2003) 14(Suppl. 4):97.
43. PETERSON DE: Research advances in oral mucositis. Curr. Opin. Oncol. (1999) 11:261-266.
44. KOSTLER WJ, HEJNA M, WENZEL C et al.: Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA: A. Cancer J. Clin. (2001) 52(5):290-315.
45. FULTON JS, MIDDLETON GJ, MCPHAIL JT: Management of oral complications. Semin. Oncol. Nurs. (2002) 18:28-35.
46. SONIS ST, FEY EG: Oral complications of cancer therapy. Oncology (2002) 16:680-686.
47. KHAN SA, WINGARD JR: Infection and mucosal injury in cancer treatment. JNCI (2001) 29:31-36.
48. WILKES JD: Prevention and treatment of oral mucositis following cancer chemotherapy. Semin. Oncol. (1998) 25:538-551.
49. PETERMAN A, CELLA D, GLANDON G, DOBREZ D, YOUNT S: Mucositis in head and neck cancer: economic and quality of life outcomes. JNCI (2001) 29:45-51.
50. YEAGER K, WEBSTER J, CRAIN M, KASOW J, MCGUIRE D: Implementation of an oral care standard for leukemia and transplantation patients. Cancer Nurs. (1998) 23:40-47.
51. KENNY S: Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nurs. (1990) 13:345-353.
52. LARSON P, MIASKOWSKI C, MACPHAIL L et al.: The PRO-Self Mouth Aware Program: an effective approach for reducing chemotherapy-related mucositis. Cancer Nurs. (1998) 21:263-268.
53. BECK S: Impact of a systematic oral care protocol on stomatitis after chemotherapy. Cancer Nurs. (1979) 2:185-199.
54. GRAHAM K, PECORARO D, VENTURA M, MEYER C: Reducing the incidence of stomatitis using a quality assessment and improvement approach. Cancer Nurs. (1993) 16:117-122.
55. MCGUIRE D, OWEN D, PETERSON D: Nursing intervention for acute oral pain and mucositis. Oncol. Nurs. Forum (1998) 25:341.
56. MUELLER B, MILLHEIM E, FARRINGTON E, BRUSKO C, WISER T: mucositis management practices for hospitalized patients: national survey. J. Pain Symptom Manage. (1995) 10:510-520.